Biocon Pharma gets nod for Tacrolimus capsule in China for organ transplant patients
Bangalore: Biocon has announced that Biocon Pharma Limited, a wholly owned subsidiary of the Company, has received approval for Tacrolimus capsule in 0.5mg, 1mg and 5mg strengths, from the National Medical Products Administration (NMPA), China.
Tacrolimus is an immunosuppressant used in the treatment of organ transplant patients, which reduces the body’s ability to reject a transplanted organ.
"The approval further adds to Biocon’s portfolio of complex drug products and will be commercialised in the region expeditiously," the Company stated in a BSE filing.
Medical Dialogues team had earlier reported that Biocon and its European partner, Zentiva, had received a Decentralized Procedure (DCP) approval for its complex formulation, Liraglutide, in the European Union (EU). The approval was for the generic versions of Victoza to treat Type-2 Diabetes and Saxenda used in the treatment of weight management.
Biocon Limited, publicly listed in 2004, is an innovation-led, global biopharmaceutical company. It has developed and commercialized novel biologics, biosimilars and complex small molecule APIs in India and several key global markets, as well as generic formulations in the US and Europe.
Read also: Biocon Chief Kiran Mazumdar-Shaw conferred Jamsetji Tata Award by Indian Society for Quality
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.